Nkarta Appoints SVP & CMO

Nkarta Therapeutics has named Kanya Rajangam, M.D., Ph.D., as senior vice president and chief medical officer.  

Dr. Rajangam, who will be joining the company in December, is an experienced biotechnology executive with a track record of successfully developing cancer therapies.  She replaces interim chief medical officer, Angela Shen, M.D., M.B.A. 

"We are thrilled to have Kanya join our team, and we look forward to her leadership in bringing our promising technology to patients in need," said Paul Hastings, president and chief executive officer of Nkarta. "Her extensive and successful drug development experience will serve us well as we embark on advancing our Natural Killer cell therapy into the clinic with our first Investigational New Drug submission planned for next year.  I’d like to thank Angela Shen for laying the foundation for our continued success and for her many other contributions to Nkarta over the past two years."   
 

Dr. Rajangam most recently served as chief medical officer at Atara Biotherapeutics where she was responsible for the development of allogeneic and autologous T-cell therapies for oncology, neurology and infectious disease. Prior to Atara, she was chief medical officer of Cleave Biosciences, where she led clinical development of the company’s oncology pipeline. 

-----------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.